This novel monoclonal immunoglobulin, Pritoxaximab – formerly known as DXX00601 – shows remarkable opportunity within the treatment of critical immune disease (TRALI). Developed by scientists, Pritoxaximab operates https://www.targetmol.com/compound/pritoxaximab